Core Viewpoint - Hagens Berman is notifying investors about a pending securities class action against F5, Inc. due to allegations of misleading statements regarding the security of its BIG-IP products, which resulted in significant financial losses for investors [1][2]. Group 1: Allegations and Impact - The lawsuit claims that F5 executives misled the market about the security of its core products, particularly after a sophisticated nation-state threat actor allegedly accessed F5's systems and exfiltrated sensitive source code [2][4]. - Following the revelation of the security breach in October 2025, F5's market value dropped by over $2 billion due to a significant decline in stock price [2]. - The breach was disclosed on October 15, 2025, revealing that a nation-state actor had maintained long-term access to F5's systems, which included the BIG-IP product development environment [7]. Group 2: Financial Performance and Guidance - F5's disappointing 4Q FY25 results, released on October 27, 2025, indicated a significant reduction in expected sales and renewals, elongated sales cycles, and increased expenses due to ongoing remediation efforts [7]. - The stock price fell by $22.83, or 7%, the day after the poor performance announcement, which was compounded by several analyst downgrades [7]. - The class period for the lawsuit is defined as October 28, 2024, to October 27, 2025, with a lead plaintiff deadline set for February 17, 2026 [5].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its drug candidate AMT-130 and its regulatory prospects with the FDA [1][11]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, including Huntington's disease (HD) [3]. - The company's leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal inherited disorder with no existing cure [4]. Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130, known as the Pivotal Study, in March 2022 [4]. - The FDA had previously agreed that the Pivotal Study would not include a placebo comparator, allowing results to be compared to an external historical dataset, ENROLL-HD, for potential BLA submission [5]. Investor Communication and Stock Performance - On September 24, 2025, uniQure announced topline results from the Pivotal Study, leading to a significant increase in share price from $13.66 to $47.50, a nearly 250% rise [7][8]. - By October 29, 2025, shares were trading above $70.00, and the company raised approximately $345 million through a public offering shortly after the positive study results [9]. Allegations of Misrepresentation - The lawsuit alleges that uniQure misrepresented the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline, leading to inflated stock prices based on misleading information [11]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the study data was adequate for BLA submission, resulting in a stock price drop of over 49% [10]. Legal Process for Investors - Investors who acquired uniQure shares during the class period may seek to be appointed as lead plaintiffs by April 13, 2026, to represent the class in the lawsuit [2][12].

Core Viewpoint - The SLM Corporation, also known as Sallie Mae, is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with investors having until February 17, 2026, to seek lead plaintiff status [1]. Company Overview - SLM Corporation, through its subsidiaries, originates and services private education loans (PELs) [2]. Allegations of the Lawsuit - The lawsuit claims that during the class period, SLM made false or misleading statements and failed to disclose significant increases in early-stage delinquencies, leading to an overstatement of the effectiveness of its loss mitigation and loan modification programs [3]. - On August 14, 2025, TD Cowen reported a 49 basis points month-over-month increase in delinquencies for July 2025, which contradicted SLM's CFO's earlier assurances about delinquency rates following normal seasonal trends. Following this report, SLM's stock price fell by approximately 8% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who invested in SLM securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 and $8.4 billion over the past five years [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug, setrusumab, during the specified class period [2][3][5]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][5]. - The case is titled Bailey v. Ultragenyx Pharmaceutical Inc., et al, and is being heard in the United States District Court for the Northern District of California [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Group 2: Allegations - The complaint alleges that Ultragenyx made false and misleading statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients [3]. - It is claimed that Ultragenyx downplayed the risks associated with the Phase III Orbit study, which may not have achieved a statistically significant reduction in annualized fracture rate [3]. - The lawsuit asserts that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [3]. Group 3: Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - Investors can file to be lead plaintiff by the April 6, 2026 deadline or choose to remain absent from the class [6]. - The law firm offers a free case evaluation for investors who experienced losses related to Ultragenyx [6][7].

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Kyndryl is a provider of enterprise technology services, offering advisory, implementation, and managed service capabilities to customers in over 60 countries. It is recognized as the world's largest IT infrastructure services provider [4]. Allegations and Financial Mismanagement - The lawsuit alleges that Kyndryl misrepresented its cash management practices, including the drivers of its adjusted free cash flow metric and the effectiveness of its internal controls over financial reporting for FY2025 and the first three quarters of FY2026 [5]. Stock Performance and Market Reaction - On February 9, 2026, Kyndryl announced a delay in releasing its fiscal Q3 2026 financial statement due to an accounting review of its cash management practices, which led to the immediate departures of its CFO and General Counsel. This announcement resulted in a stock price drop of $12.90 per share, or 55%, from $23.49 on February 8, 2026, to $10.59 on February 9, 2026 [6][7].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Plug Power provides hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets and develops infrastructure such as hydrogen production plants [4]. Legal Proceedings - Investors have until April 3, 2026, to request to lead the case in the U.S. District Court for the Northern District of New York, under the caption Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. Allegations - The lawsuit claims that Plug Power materially overstated the likelihood of receiving a $1.66 billion loan guarantee from the U.S. Department of Energy, which was intended to finance the construction of hydrogen production facilities [4]. Stock Performance - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the announcement of the abrupt departure of its CEO and President [5]. - On November 10, 2025, the stock fell by $0.09 per share (3.4%) after the company suspended activities under the DOE loan program [6]. - A further drop of $0.48 per share (17.6%) occurred on November 14, 2025, after reports confirmed the suspension of plans to construct hydrogen production facilities, jeopardizing the $1.66 billion DOE loan [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud, following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Ardent Health, Inc. operates acute care hospitals and other healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Fraud - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method, which inflated reported accounts receivable and delayed loss recognition [4]. Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased its professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 per share [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Postiwala v. Ardent Health, Inc., et al. [3].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and certain senior executives for securities fraud, following a significant drop in stock price attributed to potential violations of federal securities laws [1][3]. Company Overview - BellRing Brands, Inc. develops, markets, and sells "convenient nutrition" products, primarily known for its ready-to-drink protein shakes under the Premier Protein brand [4]. Allegations of Securities Fraud - The lawsuit claims that BellRing misrepresented sales growth as being driven by increased consumer demand, while in reality, sales were inflated due to key customers stockpiling inventory. The company downplayed competitive pressures, asserting it had a "competitive moat" in the ready-to-drink category [4]. - The complaint is based on violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in BellRing securities [3]. Stock Price Decline - On May 6, 2025, BellRing's CFO disclosed that several key retailers had reduced their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth. This announcement caused the stock price to drop by $14.88, or 19%, from $78.43 to $63.55 per share [5]. - Following the Q3 2025 financial results reported on August 4, 2025, which included a narrowed fiscal year outlook, the stock price fell by $17.46, or nearly 33%, from $53.64 to $36.18 per share on August 5, 2025 [6][7].

Core Viewpoint - Agilon Health, Inc. is facing a securities fraud lawsuit initiated by the Rosen Law Firm, with a lead plaintiff deadline set for March 2, 2026, for investors who purchased securities between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that Agilon's management made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [1] - It is claimed that Agilon overstated the positive financial impact from strategic actions taken to mitigate risks, leading to materially false representations about the company's business and prospects [1] - Investors are encouraged to join the class action without incurring out-of-pocket fees, as the Rosen Law Firm operates on a contingency fee basis [1] Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [1] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [1] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in handling such cases [1]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].